Nasal vaccine shows promise in reducing whooping cough spread in the U.S

A new nasal vaccine for whooping cough may help reduce the spread of the disease, which is currently rising in the U.S. Unlike traditional vaccines, this new option targets the upper respiratory tract, preventing bacteria transmission even in vaccinated individuals. The vaccine uses a novel adjuvant called T-vant, which enhances the immune response in the respiratory system. In studies, mice given the nasal vaccine showed no bacteria in their lungs, while those with the traditional vaccine still had the bacteria present. This development comes as whooping cough cases have surged five-fold in the U.S. over the past year. The new vaccine could potentially lead to better control of the disease, which affects millions globally, especially infants and those with weakened immune systems.